Yinuo Thinking (688710): The first stock of a national pharmaceutical CRO, the leader in the domestic safety assessment field.

The demand for safety evaluation outsourcing services is strong, with high entry barriers in the Industry. Safety evaluation, as a Heavy Assets Industry, has a relatively high threshold for entry, and pharmaceutical companies have a strong willingness to outsource. Global market: In 2023, the safety evaluation outsourcing market size is approximately 7-8 billion USD, accounting for the pre-clinical stage.

China MerchantsDec 18 00:00

Third Quarter Report 2024

SZSIOct 30 00:00 · Announcements

Express News | Porton Pharma Solutions and Yinosi have reached a global strategic cooperation.

BreakingsOct 24 21:35

The amount of funds raised for the investment project has been significantly reduced, and Yinoosi has tested the "temperature" of the CRO industry.

①Yinuosi originally planned to raise 1.602 billion yuan, but only raised 0.672 billion yuan in reality, leading to a significant reduction in the investment amount of some fundraising projects and the cancellation of the supplementary flow project. ②Due to the slowdown in investment and financing, china meheco group's research and development expenditure growth rate has also started to slow down, impacting the performance of many upstream CRO companies including Yinuosi.

cls.cnOct 16 15:53

Express News | Yinuo Think: There is no significant information that should be disclosed but has not been disclosed.

BreakingsOct 9 18:50

Express News | YinuoSi: The company and its subsidiaries have obtained GLP certification.

BreakingsOct 8 16:23